Search for stocks /

Rossari Biotech Ltd Q2 FY26 — When 4,280 Products Earn You 12% ROE and a Seat Next to Pidilite in the Attendance Register


1. At a Glance

If chemistry had a stand-up act, Rossari Biotech would open the show with a lab coat and a nervous smile.
At ₹ 648 per share, market cap ₹ 3,589 cr, this “specialty-chemical” star has become a specialist in delivering steady growth with Bollywood-movie patience.
Q2 FY26 revenue jumped 18 % YoY to ₹ 586 cr, but PAT crawled only 4 % to ₹ 37 cr. The OPM 12 % flatlined, ROE 12 %, ROCE 15.8 %, and yet the stock has slipped 21 % YoY—like a topper who still gets scolded for handwriting.
The P/E 26× is half of Pidilite’s, but double of your comfort zone. So yes, chemistry is profitable; just not explosively so.


2. Introduction

Rossari started in 2003 mixing textile auxiliaries and dreams of global glory. Two decades later, it’s a mid-cap that smells faintly of detergent and ambition.
Its three pillars—Home & Personal Care (HPPC), Textile Specialty Chemicals (TSC), and Animal Health & Nutrition (AHN)—cover everything from fabric softeners to poultry enzymes. Basically, from your shirt to your shampoo to your chicken—Rossari’s molecules are everywhere.

But investors wanted the next Pidilite; what they got was the next “patient compounding case study.”
Margins hover around 12–13 %, management speaks fluent “capacity expansion,” and the chart looks like a sine wave of optimism and boredom.


3. Business Model – WTF Do They Even Do?

Let’s decode the periodic table of Rossari:

  • HPPC (76 %) – Cleaning chemicals, detergents, coatings, inks, ceramics, water-treatment blends—basically the stuff that makes other stuff shine. The fastest-growing segment and darling of FMCG tie-ups.
  • TSC (19 %) – Legacy textile aids: dyeing auxiliaries, finishing agents, digital printing chemistry. Once the core, now the side hustle.
  • AHN (5 %) – Poultry feed supplements, pet grooming and treats—because even chickens deserve glossy feathers.

They manufacture across 7 plants in Gujarat, 3.3 lakh MTPA total capacity, distribute through 406 distributors across 24 states, and export to 50 countries.
Two R&D centres—Silvassa and IIT Bombay—churn out new molecules faster than SEBI circulars.


4. Financials Overview

MetricQ2 FY26Q2 FY25Q1 FY26YoY %QoQ %
Revenue₹ 586 cr₹ 498 cr₹ 544 cr+17.6 %+7.7 %
EBITDA₹ 72 cr₹ 66 cr₹ 68 cr+9 %+6 %
PAT₹ 37 cr₹ 35 cr₹ 34 cr+4 %+9 %
EPS (₹)6.666.396.07+4 %+9 %

Annualised EPS ≈ ₹ 26.6 → P/E ≈ 24×

🧪 Commentary: Steady chemistry—no explosions, no leaks. Margins behaving like disciplined students in a lab safety video.


5. Valuation Discussion – Fair Value Range Only

(a) P/E Approach

Sector average ≈ 32× ; EPS ₹ 24.7 → Fair range ₹ 600 – ₹ 790.

(b) EV/EBITDA

EV ₹ 3,889 cr ; EBITDA ₹ 280 cr (TTM) → 13.9×. Sector median ≈ 15× → ₹ 630 – ₹ 700.

(c) DCF (Discounted Chemical Fantasy)

5-yr CAGR 12 %, WACC 9 %, terminal growth 3 % → ₹ 650 – ₹ 720.

📘 Fair Value Range = ₹ 630 – ₹ 750
(Educational purpose only. Not investment advice.)


6. What’s Cooking – News, Triggers, Drama

  • 16 Oct 2025: Q2 results—revenue ₹ 586 cr, EBITDA ₹ 72 cr, PAT ₹ 37 cr; company announces USD 8 mn Saudi investment.
error: Content is protected !!